This Solicitation opportunity from Department Of Health And Human Services was posted on May 14, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
BioStabilization Systems (BoSS)
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The BioStabilization Systems (BoSS) program, led by ARPA-H within the Department of Health and Human Services, seeks innovative solutions to revolutionize the stabilization, manufacturing, and distribution of live cell-based therapies by eliminating the reliance on ultra-cold storage conditions. This program aims to develop scalable bioprocessing systems that enable the production of thermally stable cells, which would significantly enhance the accessibility and resilience of biologics manufacturing and distribution. BoSS technologies are poised to impact a broad spectrum of healthcare areas, including biotechnology, regenerative medicine, genetic testing, blood supply, and wound repair. The solicitation ARPA-H-SOL-26-136 invites proposals from performers and Independent Verification and Validation (IV&V) partners, with distinct submission deadlines for solution summaries—February 19, 2026, for performers and April 17, 2026, for IV&V partners—and a final Solution Pitch deadline for IV&V proposers extended to May 21, 2026. Several amendments to the original solicitation have been issued to clarify requirements and update submission materials. Amendment 4 specifically extends the Solution Pitch deadline for IV&V partners and revises attachments to remove certain references, emphasizing that this extension does not apply to IV&V Solution Summaries. Earlier amendments refined the ISO by clarifying out-of-scope examples, updating capability requirements, allowable partner entity types, and reporting requirements, as well as correcting terminology and formatting errors. The solicitation details evaluation criteria and encourages strategic partnerships under multiple Other Transaction Agreements. Interested parties must submit proposals through the designated portal and closely monitor updates to ensure compliance with the amended documents. The program office, based in Washington, D.C., provides informational resources and proposer engagement events to support applicants in this cutting-edge biotechnology endeavor.
General Info
Agency
NAICS
Place of Performance
Washington, DC, 20005, USASet-Aside
Timeline
Submission Closed
Organization & Contact Information
Full Description
Amendment 4:
The purpose of this amendment is to amend the BoSS ISO. An updated version of the ISO, with changes in red font, is included as an attachment to this amendment. These changes are applicable to IV&V proposers only.
Changes to the ISO include:
- extending the Solution Pitch deadline for IV&V proposers to May 21, 2026.
- Attachment 3A Cost Proposal Narrative removes references to TA1/TA2.
- Attachment 4A Cost Proposal Spreadsheet removes references to TA1/TA2.
Please be sure to use the new Attachments listed above in your submission, which can be found in the Attachments section of this poting. This Amendment DOES NOT extend the deadline for IV&V Solution Summaries.
------------------------------------------------------------------------------------------------------------
Amendment 3:
The purpose of this amendment is to amend the Attachments. Changes to the attachments are listed below:
- Attachment 3 Cost Proposal Narrative: references to "lead organization" were changes to "lead member." See red text on the cover page.
- Attachment 4 Cost Proposal Spreadsheet: On the General tab in the yellow box, under the "Instructions for using this template." See red text on the General tab.
Please carefully review the amended ISO for all changes.
------------------------------------------------------------------------------------------------------------
Amendment 2:
The purpose of this amendment is to amend the BoSS ISO. An updated version of the ISO, with changes in red font, is included as an attachment to this amendment.
Changes to the ISO include (but are not limited to):
- clarification of examples of out-of-scope approaches (Table 1)
- update to capability requirements (Section 1.3 Program Overview)
- update to allowable IV&V partner entity types (Section 2)
- update to reporting requirements (Section 3.4 Programmatic Deliverables)
Please carefully review the amended ISO for all changes.
------------------------------------------------------------------------------------------------------------
Amendment 1 corrects a formatting error on references to Table 2.
------------------------------------------------------------------------------------------------------------
Program Description:
The BioStabilization Systems (BoSS) program aims to transform how live cell-based therapies are stabilized, manufactured, and distributed. At its core, BoSS addresses a foundational bottleneck in the delivery of advanced cell and gene therapies (CGTs): the critical dependence on ultra-cold conditions (-80 to -196˚C) for storage and transport. BoSS will yield a bioprocessing system that enables scalable production of thermally stable cells, paving the way for a new era of efficient and resilient manufacturing and distribution of biologics without any need for cold storage. BoSS-developed technologies will also accelerate many other avenues in biotechnology that directly impact healthcare, including bio-surveillance, regenerative medicine, large-scale genetic testing, blood product supply, and wound repair, in addition to improving access to a wide range of existing biotherapeutics.
Solution Summaries are required:
For consideration as a Performer:
- Solution Summary due date: February 19th, 2026 5:00 PM ET
For consideration as an IV&V partner:
- Solution Summary due date: April 17th, 2026 5:00 PM ET
Interested parties are invited to review the attached BoSS Innovative Solutions Opening (ISO) ARPA-H -SOL-26-136.
Submissions must be made to:
- Solution Summary Submission Site: https://solutions.arpa-h.gov/Submit-Solution/
Please ensure to follow this opportunity for any updates.
For more information on the BoSS program visit: https://arpa-h.gov/explore-funding/programs/boss.
For information on Proposer's Day details and registration information, please see Special Notice ARPA-H-SN-26-137.